EUVIMEDEUVIMED entdecken
Crossref

Cost-effectiveness analysis of first-line serplulimab plus chemotherapy for advanced squamous non-small-cell lung cancer in China: based on the ASTRUM-004 trial

Heng Xiang, Kehui Meng, Meiyu Wu, Chongqing Tan

Expert Review of Pharmacoeconomics & Outcomes Research · 2024

DOI: 10.1080/14737167.2024.2379600 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2024. Verfasst von Heng Xiang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Quality-Adjusted Life Years. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: In the ASTRUM-004 trial, serplulimab plus chemotherapy demonstrated significantly improved survival and controllable safety. This study assessed the cost-effectiveness of serplulimab plus chemotherapy in advanced squamous non-small cell lung cancer (sqNSCLC), considering the perspective of the Chinese healthcare system. METHODS: A decision tree and a Markov model were constructed to simulate the treatment. The interesting results included total cost, life-years (LYs), quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs). Scenario, one-way and probabilistic sensitivity analyses were used to examine model instability. RESULTS: Compared with placebo plus chemotherapy, serplulimab plus chemotherapy had an ICER of $55,539.46/QALY ($47,278.84/LY). The ICERs were estimated to be $58,706.03/QALY, $48,978.34/QALY and $59,709.54/QALY inpatients with programmed death-ligand 1 expression level of tumor proportion score (TPS) < 1%, 1% ≤ TPS < 50%, and TPS ≥ 50%. The cost-effective prices of serplulimab were $168.276/100 mg, $349.157/100 mg, and $530.039/100 mg at the willingness-to-pay threshold of $12,574.30/QALY, $25,148.60/QALY, and $37,722.90/QALY. Patient weight and price of serplulimab created the most significant impact. Presently, the probability of serplulimab plus chemotherapy being cost-effective was 14.15%. CONCLUSION: Compared with placebo plus chemotherapy, serplulimab plus chemotherapy might not be cost-effective in the first-line treatment for advanced sqNSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Benefit AnalysisCarcinoma, Non-Small-Cell LungLung NeoplasmsQuality-Adjusted Life YearsAntineoplastic Combined Chemotherapy ProtocolsMarkov ChainsDecision TreesHumansChinaAntibodies, Monoclonal, HumanizedB7-H1 AntigenSurvival RateCost-Effectiveness Analysis

Stichwörter der Autor:innen

Cost-effectivenessfirst-line treatmentserplulimabsqNSCLCsquamous non-small cell lung cancer

Substanzen

Antibodies, Monoclonal, HumanizedCD274 protein, humanB7-H1 Antigen

Autor:innen und Institutionen

  • Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Institute of Clinical Pharmacy, Central South University, Changsha, Hunan, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Xiang, H., Meng, K., Wu, M., & Tan, C. (2024). Cost-effectiveness analysis of first-line serplulimab plus chemotherapy for advanced squamous non-small-cell lung cancer in China: based on the ASTRUM-004 trial. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2024.2379600

Vancouver

Xiang H, Meng K, Wu M, Tan C. Cost-effectiveness analysis of first-line serplulimab plus chemotherapy for advanced squamous non-small-cell lung cancer in China: based on the ASTRUM-004 trial. Expert Review of Pharmacoeconomics & Outcomes Research. 2024. doi:10.1080/14737167.2024.2379600

BibTeX
@article{Xiang2024,
  author = {Xiang, Heng and Meng, Kehui and Wu, Meiyu and Tan, Chongqing},
  title = {Cost-effectiveness analysis of first-line serplulimab plus chemotherapy for advanced squamous non-small-cell lung cancer in China: based on the ASTRUM-004 trial},
  journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year = {2024},
  doi = {10.1080/14737167.2024.2379600}
}
Kostenlos starten →